Testing a biosimilar ipilimumab for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer (hepatocellular carcinoma) that cannot be treated with surgery or other local therapies.
- You must be between 18 and 65 years old and weigh between 50 kg and 85 kg (110–187 lbs).
- You cannot have had any prior systemic treatment (like chemotherapy or immunotherapy) for advanced liver cancer.
- Your liver function must be good (Child-Pugh class A) and your overall health status should be normal (ECOG 0).
- You must have at least one tumor that can be measured on a scan, and it cannot be one that was previously treated with surgery or radiation.
- If you have hepatitis B or C, it must be well-controlled with medication, and you must agree to continue treatment during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HLX13, against a standard drug called Yervoy for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if HLX13 works as well as Yervoy and has similar safety.
This study tests a new way of giving immunotherapy drugs for advanced liver cancer that cannot be removed by surgery. The goal is to find the best dose for each patient, which may help control the cancer with fewer side effects.
This trial tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus targeted radiation (SBRT) for people with liver cancer that is advanced but has not spread outside the liver. The goal is to see if this approach can shrink tumors and make them easier to remove with surgery.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy pill (regorafenib) for people with advanced liver cancer that has progressed after first-line treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.